Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Alzheimer’s wonder drug blocked on NHS over cost
Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators declaring it safe
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research
New Alzheimer’s drug approved in UK, but government won’t pay for it
The new Alzheimer’s drug Kisunla has been approved in the UK, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers. It is the second Alzheimer’s drug to receive such a mixed reception within months.
New Alzheimer’s drug donanemab rejected for widespread use in NHS
A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the National Institute for Health and Care Excellence (Nice) stating the treatment "does not currently demonstrate value for the NHS".
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
NICE rejects Alzheimer’s drug donanemab owing to cost and “significant health risks”
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the “relatively small benefit” it provides does not outweigh its cost.1 The draft guidelines,
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to t
Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being
WKBW
1h
Researchers at UB working to create vaccine to treat Alzheimer's disease
There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...
Yahoo
3h
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
The National Institute for Health and Care Excellence (Nice) confirmed on Wednesday that it would not fund
donanemab
- the ...
Outsourcing-pharma
16h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Workers reject new contract
Settles civil lawsuit
NK troops in RU confirmed
Joins Republican Party
Suffers 'debilitating' stroke
'Tarzan' star Ron Ely dies
Closing argument speech plan
Court orders new sentence
$3.9B storm relief proposal
Yelp disables reviews
Apple, Goldman Sachs fined
FDA recalls antidepressant
Dodgers legend dies
Hashem Safieddine killed
Biden says lock up Trump
US fines American Airlines
MO court upholds release
DOJ alleges racial bias
Israel strikes Lebanese city
Kentucky lawmaker dies
Timberlake postpones shows
Bird flu infects 4 in WA
DNC office shootings arrest
First father-son duo in NBA
G7 Ukraine loan advances
Settles hazardous waste suit
Existing home sales fall
Lake Erie toxic algae study
To close 150 locations
Feedback